PFIZER INC reported its experimental 25-valent pneumococcal vaccine produced antibody levels 15 times higher than its current shot in a mid-stage trial. The 25vPnC candidate outperformed Prevnar 20 across all target strains in healthy infants. This advance matters because 25vPnC could protect against 90% of disease-causing strains in children under five, exceeding current immunizations.
Pfizer pneumococcal vaccine shows strong trial results
Pfizer's experimental vaccine showed higher antibody levels in infants than current shots. The company is now starting a late-stage trial for the new candidate.
Xurve View
Insights:
Xurve View











